AstraZeneca's Imfinzi combination fails advanced lung cancer study

(Reuters) - AstraZeneca said on Wednesday a combination treatment including its lung cancer drug Imfinzi failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations. The clinical trial, called NEPTUNE, was testing Imfinzi along with FDA-approved tremelimumab and comparing the combination to platinum-based chemotherapy to treat patients whose cancer had spread to other parts of the body.London-listed AstraZeneca said though the..